Post

New research · Ophthalmology
Journal of vitreoretinal diseases · 5d
Cohort studyJournal of vitreoretinal diseases · 2026

Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.

Alexander Shaer, Tadashi Yokoi, Eshani Ragam … Carl Regillo
Read paper
OphthalmologyCohort study

Avacincaptad pegol injections rarely caused eye inflammation or infection in real-world use.

Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.

Alexander Shaer … Carl Regillo
Journal of vitreoretinal diseases · 2026
Purpose

To evaluate the real-world ocular safety profile of intravitreal (intravitreal) avacincaptad pegol for geographic atrophy (geographic atrophy) secondary to age-related macular degeneration (AMD).

Methods

This retrospective study evaluated eyes with geographic atrophy secondary to AMD, including those with concurrent neovascular AMD (nAMD) treated with avacincaptad pegol.

n = 845 eyes
Results
0.02%
one in 5,000 injections caused eye swelling or infection - very low risk
n = 845 eyes
More results

Overall, 845 eyes of 590 patients (mean age, 81.8 ± 7.6 years; 71.9% female) received 5608 avacincaptad pegol injections.

Conversion occurred in 21 of 590 at-risk eyes (3.6%; 4.3% annualized) after a median of 3 injections (interquartile range, 3-5; range, 1-22).

More results

At baseline, nAMD was present in 25.1% of fellow eyes but accounted for 38.1% of conversions, reflecting a higher subgroup conversion rate of 5.4% (6.7% annualized).

Among 26 eyes with quiescent nAMD, reactivation occurred in 1 eye (3.8%) after a treatment-free interval of 7.5 years.

“
Conclusion

In this real-world cohort, a favorable safety profile was found with avacincaptad pegol, with low rates of inflammatory events, endophthalmitis, persistent ocular hypertension, and nAMD conversion, providing clinically relevant data to inform patient counseling and monitoring.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving